Biophytis S.A. (ALBPS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biophytis S.A. (ALBPS) has a cash flow conversion efficiency ratio of 0.472x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.69 Million ≈ $-4.32 Million USD) by net assets (€-7.82 Million ≈ $-9.14 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biophytis S.A. - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Biophytis S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Biophytis S.A. for a breakdown of total debt and financial obligations.
Biophytis S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biophytis S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Value & Income Trust
LSE:VIP
|
0.013x |
|
Trifast plc
LSE:TRI
|
0.049x |
|
PDG Realty S.A. Empreendimentos e Participações
SA:PDGR3
|
0.000x |
|
Inspecs Group plc
LSE:SPEC
|
0.071x |
|
Boxlight Corp Class A
NASDAQ:BOXL
|
0.143x |
|
Thiensurat Public Company Limited
BK:TSR
|
-0.011x |
|
Shield Therapeutics plc
LSE:STX
|
0.303x |
|
Protagenic Therapeutics
NASDAQ:PTIX
|
0.087x |
Annual Cash Flow Conversion Efficiency for Biophytis S.A. (2013–2024)
The table below shows the annual cash flow conversion efficiency of Biophytis S.A. from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see ALBPS market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-9.70 Million ≈ $-11.34 Million |
€-8.64 Million ≈ $-10.10 Million |
0.891x | -73.09% |
| 2023-12-31 | €-3.89 Million ≈ $-4.55 Million |
€-12.87 Million ≈ $-15.05 Million |
3.310x | -66.69% |
| 2022-12-31 | €-1.91 Million ≈ $-2.23 Million |
€-18.99 Million ≈ $-22.20 Million |
9.936x | +338.23% |
| 2021-12-31 | €5.71 Million ≈ $6.67 Million |
€-23.80 Million ≈ $-27.82 Million |
-4.171x | -188.88% |
| 2020-12-31 | €6.83 Million ≈ $7.99 Million |
€-9.86 Million ≈ $-11.53 Million |
-1.444x | -171.15% |
| 2019-12-31 | €-7.53 Million ≈ $-8.80 Million |
€-15.27 Million ≈ $-17.86 Million |
2.029x | +217.92% |
| 2018-12-31 | €7.01 Million ≈ $8.19 Million |
€-12.06 Million ≈ $-14.10 Million |
-1.721x | -317.79% |
| 2017-12-31 | €21.19 Million ≈ $24.77 Million |
€-8.73 Million ≈ $-10.20 Million |
-0.412x | +71.94% |
| 2016-12-31 | €4.52 Million ≈ $5.28 Million |
€-6.63 Million ≈ $-7.75 Million |
-1.468x | -433.55% |
| 2015-12-31 | €11.67 Million ≈ $13.64 Million |
€-3.21 Million ≈ $-3.75 Million |
-0.275x | -147.13% |
| 2014-12-31 | €-1.13 Million ≈ $-1.32 Million |
€-658.89K ≈ $-770.31K |
0.584x | -70.26% |
| 2013-12-31 | €-409.32K ≈ $-478.54K |
€-803.29K ≈ $-939.14K |
1.962x | -- |
About Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement w… Read more